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Recently, the RNActive technology has been developed to
generate highly active cancer vaccines. The antigen of
choice is encoded by a sequence engineered mRNA that
increases antigen expression up to 5 orders of magnitude.
Immunogenicity of the RNActive vaccines is ensured by a
built-in adjuvant function based on complexation of half
of the mRNA with protamine that leads to activation of
toll-like receptor 7 (TLR7). 5 intradermal administrations
of a mRNA vaccine encoding PSA, PSCA, PSMA, and
STEAP (CV9103) were tested in phase I/IIa studies in 44
patients with castrate-resistant prostate carcinoma (PCA).
The vaccine was well tolerated and induced antigen-
specific immunogenicity assessed by ex-vivo assays against
all encoded antigens independent of the HLA-profile of
patients. The overall immune response rate in evaluable
patients was 80 %, close to 60% of these reacted against
multiple antigens. In the subgroup of 36 patients with
metastatic CRPC a median overall survival of over
30 months was estimated whereas the predicted survival
according to the Halabi nomogram was 16.5 months.
Patients responding to at least one tumor antigen had
a reduced risk to die during the observation period com-
pared to immunological non-responders, although the
Halabi-predicted survival of both groups was similar.
Responses against multiple antigens seemed to correlate
even more strongly with improved survival, with patients
reacting against 3 antigens s showing the longest survival.
The results of this clinical study demonstrated high immu-
nogenicity paired with a good safety profile for this new
prostate cancer vaccine. The apparent correlation of
immunogenicity with prolonged survival despite unfavor-
able patient characteristics according to the Halabi-score
suggests a therapeutic effect. CV9104, an advancement
of CV9103 encoding two more antigens is currently tested
in a randomized, placebo-controlled phase IIb trial with
overall survival as primary endpoint. It appears that
mRNA based vaccines offer an ideal basis to exploit
the potential of nucleotide based cancer vaccines for the
benefit of patients. Precise data will be presented at the
meeting.
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